C. Trépo

Leroy, C. Jacquelinet, T. Asselah, 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma.

Miran Kim, J. Wands, A. von dem Bussche, 2004, Gastroenterology.

Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region.

C. Trépo, S. Tong, L. Vitvitski, 1990, Virology.

High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology.

M. Chevallier, F. Zoulim, I. Chemin, 2001, Journal of hepatology.

Rise in gamma interferon expression during resolution of duck hepatitis B virus infection.

F. Zoulim, C. Trépo, L. Cova, 2006, The Journal of general virology.

Evolution of hepatitis B viral load and viral genome sequence during adefovir dipivoxil therapy

P. Marcellin, F. Zoulim, S. Pol, 2004, Journal of viral hepatitis.

Current Management Strategies for Hepatitis B in the Elderly

F. Zoulim, C. Trépo, P. Merle, 2001, Drugs & aging.

Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.

F. Zoulim, C. Trépo, C. Jamard, 2001, Journal of hepatology.

Characterization of the Antiviral Effect of 2′,3′-Dideoxy-2′, 3′-Didehydro-β-l-5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model

Yung-chi Cheng, M. Chevallier, F. Zoulim, 2000, Antimicrobial Agents and Chemotherapy.

Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance

F. Zoulim, C. Trépo, C. Pichoud, 1999, Hepatology.

New Antiviral Agents for the Therapy of Chronic Hepatitis B Virus Infection

F. Zoulim, C. Trépo, C. Trépo, 1999, Intervirology.

Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy.

F. Zoulim, C. Trépo, C. Trépo, 1998, Journal of hepatology.

Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure.

M. Chevallier, F. Zoulim, C. Trépo, 2005, Journal of hepatology.

Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles.

R. Dwek, F. Zoulim, P. Roingeard, 2006, The Journal of general virology.

Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.

D. Roulot, A. Tran, F. Degos, 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Liver histological alterations in patients with chronic hepatitis C and normal ALT levels in the city of Salvador, Northeast-Brazil.

C. Trépo, A. Lyra, R. Paraná, 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Anti-hepatitis C virus core IgM antibodies correlate with hepatitis C recurrence and its severity in liver transplant patients

C. Trépo, S. Guichard, M. Adham, 2000, Gut.

Intravenous Vitamin Complexes Used in Sporting Activities and Transmission of HCV in Brazil

C. Trépo, R. Paraná, L. Lyra, 1999, American Journal of Gastroenterology.

Impact of hepatitis G virus co-infection on the course of hepatitis C virus infection before and after liver transplantation.

C. Trépo, S. Guichard, C. Ducerf, 1998, Journal of hepatology.

The carboxy-terminal cross-linked telopeptide of type I collagen (ICTP) is a potential serum marker of ongoing liver fibrosis.

S. Ricard-Blum, M. Chevallier, P. Chossegros, 1996, Clinica chimica acta; international journal of clinical chemistry.

The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial.

H. Godinot, C. Trépo, J. Gaudin, 2008, Liver.

A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group.

X. Causse, C. Trépo, J. Zarski, 1994, Journal of hepatology.

Randomized controlled trial of adenine arabinoside 5′‐monophosphate in chronic active hepatitis B: Comparison of the efficacy in heterosexual and homosexual patients

P. Marcellin, D. Ouzan, C. Degott, 1989, Hepatology.

Therapeutic activity of vidarabine in symptomatic chronic active hepatitis related to HBV.

M. Chevallier, P. Chossegros, D. Ouzan, 1986, Journal of hepatology.

Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.

M. Chevallier, F. Zoulim, C. Trépo, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

F. Zoulim, C. Trépo, P. Miossec, 2007, Rheumatology.

Anti‐Golgi complex antibodies during pegylated‐interferon therapy for hepatitis C

C. Trépo, R. Paraná, Z. Andrade, 2006, Liver international : official journal of the International Association for the Study of the Liver.

Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases.

F. Zoulim, I. Chemin, C. Trépo, 2015, Clinics and research in hepatology and gastroenterology.

Diversity of Hepatocellular Carcinoma Clones Bearing Hematopoietic Malignancies‐Related Chromosomal Translocation

F. Zoulim, M. Marion, C. Trépo, 2014, Journal of cellular biochemistry.

Histological Benefit of Retreatment by Pegylated Interferon Alfa‐2b and Ribavirin in Patients with Recurrent Hepatitis C Virus Infection Posttransplantation

C. Trépo, P. Pradat, J. Mabrut, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Benefit of Sustained Virological Response to Combination Therapy on Graft Survival of Liver Transplanted Patients with Recurrent Chronic Hepatitis C

F. Zoulim, C. Trépo, P. Pradat, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Triple Antiviral Therapy with Amantadine for IFN-Ribavirin Nonresponders with Recurrent Posttransplantation Hepatitis C

C. Trépo, P. Pradat, M. Adham, 2005, Transplantation.

Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study

P. Marcellin, O. Weiland, A. Alberti, 2002, Hepatology.

Prevalence of exposure to aflatoxin and hepatitis B and C viruses in Guinea, West Africa.

C. Wild, C. Trépo, B. Sylla, 1995, Natural toxins.

HCV: epidemiology, modes of transmission and prevention of spread.

C. Trépo, P. Pradat, 2000, Bailliere's best practice & research. Clinical gastroenterology.

Prevalence of hepatitis C infection among general practice patients in the Lyon area, France

C. Trépo, P. Pradat, F. Bailly, 2004, European Journal of Epidemiology.

Hepatitis C virus infection in Western Europe.

C. Trépo, P. Pradat, C. Trépo, 1999, Journal of hepatology.

Treatment of recurrent hepatitis C following liver transplantation

C. Trépo, C. Ducerf, T. Bizollon, 1999, Current gastroenterology reports.

Hepatitis C virus recurrence after liver transplantation

C. Trépo, D. Mutimer, C. Ducerf, 1999, Gut.

Ultrasound detection of spontaneous hepato‐cellular carcinomas in X/myc bitransgenic mice

M. Janier, D. Vray, J. Scoazec, 2004, Liver international : official journal of the International Association for the Study of the Liver.

defovir Dipivoxil Alone or in Combination With Lamivudine in atients With Lamivudine-Resistant Chronic Hepatitis B

K. Kowdley, C. Trépo, P. Buggisch, 2003 .

Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.

M. Chevallier, T. Fontanges, C. Trépo, 2008, Gastroenterologie clinique et biologique.

Longitudinal Assessment of Histology Surrogate Markers (FibroTest–ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection

F. Zoulim, P. Landais, F. Degos, 2005, The American Journal of Gastroenterology.

Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006).

C. Trautwein, A. Burroughs, X. Forns, 2006, Journal of hepatology.

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation

M. Chevallier, C. Trépo, C. Ducerf, 1997, Hepatology.

A twelve year natural history of hepatitis C virus infection in hemodialyzed patients.

C. Trépo, A. Couroucé, N. Simon, 1994, Kidney international.

Use of the cross-reactivity between hepatitis B and non-A, non-B viruses for the identification and detection of non-A, non-B 'e' antigen.

C. Trépo, L. Vitvitski, O. Hantz, 1980, Journal of virological methods.

Identification and detection of long incubation non-A, non-B hepatitis virus and associated antigens or antibodies.

C. Trépo, L. Vitvitski, O. Hantz, 1980, Journal of virological methods.

Uncommon side‐effects of interferon

C. Trépo, F. Bailly, A. Mattei, 1997, Journal of viral hepatitis.

Translational extracts active biologically in vitro obtained from eukaryotic monolayer cells: a versatile method for viral RNA studies.

C. Trépo, D. Favre, 2001, Journal of virological methods.

Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties.

J. Dubuisson, C. Wychowski, C. Trépo, 1998, Virology.

Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks

M. Buendia, T. Möröy, C. Trépo, 1986, Nature.

Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours

G. Fourel, M. Buendia, L. Bougueleret, 1990, Nature.

Serological pattern “anti‐HBc alone”: Report on a workshop

H. Margolis, S. Günther, G. Gerken, 2000, Journal of medical virology.

Lymphotropism of hepatitis B and C viruses: an update and a newcomer

F. Zoulim, C. Trépo, J. Lamelin, 1995, International journal of clinical & laboratory research.

Antiviral activity of recombinant interferon-alpha on hepatitis A virus replication in human liver cells.

C. Trépo, A. Jouan, F. Leveque, 1995, Antiviral research.

Contribution of Aflatoxin Bf and Hepatitis B Virus Infection in the Induction of Liver Tumors in Ducks1

R. Montesano, Christopher, T. Shirai, 2006 .

Sensitivity and specificity of third‐generation hepatitis C virus antibody detection assays: an analysis of the literature

C. Trépo, D. Lanoir, F. Bailly, 2001, Journal of viral hepatitis.

Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.

V. de Lédinghen, D. Sautereau, P. Marquet, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Hepatitis C virus genotypes in a northeastern area of Brazil.

M. Reis, C. Trépo, R. Paraná, 2000, The American journal of tropical medicine and hygiene.

Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial.

R. Écochard, P. André, F. Gueyffier, 2012, Therapie.

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

C. Bain, J. Limacher, C. Féray, 2011, Gastroenterology.

Primary and memory T cell responses induced by hepatitis C virus multiepitope long peptides.

A. Pajot, C. Bain, A. Fatmi, 2006, Vaccine.

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination.

U. Spengler, C. Trépo, E. Tanaka, 1999, DNA and cell biology.

Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin

P. Marquet, A. Tran, C. Trépo, 2016, Therapeutic drug monitoring.

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal.

S. Dixit, R. Rajbhandari, C. Trépo, 2020, PLoS neglected tropical diseases.

Latent hepatitis B virus (HBV) infection and HBV DNA integration is associated with further transformation of hepatoma cells in vitro.

C. Trépo, D. Favre, M. Petit, 2003, ALTEX.

Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells.

C. Trépo, O. Vidalin, M. Major, 1996, The Journal of clinical investigation.

Congenital Malformations of the Suprahepatic Inferior Vena Cava: An Easily Overlooked Etiology of Chronic Liver Disease with Tumor-Like Nodules

J. Scoazec, C. Trépo, P. Valette, 2006, Digestive Diseases and Sciences.

Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma.

F. Zoulim, C. Trépo, C. Jamard, 1997, Journal of hepatology.

Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma

M. Buendia, T. Möröy, A. Louise, 1988, Cell.

Statements from the Taormina expert meeting on occult hepatitis B virus infection.

M. Buendia, J. Pawlotsky, F. Zoulim, 2008, Journal of hepatology.

Clinical, histologic and serologic evaluation of patients with acute non-A-E hepatitis in north-eastern Brazil: is it an infectious disease?

M. Reis, R. Santos-Jesus, C. Trépo, 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes

C. Trépo, O. Vidalin, G. Inchauspé, 1998, Hepatology.

Pre-core mutation associated with lack of hepatitis B e antigenaemia in Moroccan asymptomatic carriers of the virus.

C. Trépo, S. Benjelloun, S. Tong, 1993, Research in virology.

Natural and experimental infection of wild mallard ducks with duck hepatitis B virus.

C. Trépo, L. Cova, P. Chevallier, 1991, The Journal of general virology.

Correlation between HBV DNA detection by polymerase chain reaction and pre‐S1 antigenemia in symptomatic and asymptomatic hepatitis B virus infections

F. Zoulim, I. Chemin, C. Trépo, 1991, Journal of medical virology.

Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks.

C. Wild, R. Montesano, T. Shirai, 1990, Cancer research.

Monoclonal Antibody toa Conserved Epitope on theDuckHepatitis B VirusPre-SProtein

R. Sprengel, G. Deléage, H. Will, 1990 .

Possible prevention of chronic hepatitis B by early interferon therapy.

P. Chossegros, F. Zoulim, I. Chemin, 1990, Journal of hepatology.

Comparative study of DHBV DNA levels and endogenous DNA polymerase activity in naturally infected ducklings in France.

C. Trépo, L. Cova, B. Chomel, 1985, Journal of virological methods.

Update of the statements on biology and clinical impact of occult hepatitis b virus infection.

R. Bruno, A. Lok, T. Berg, 2019, Journal of hepatology.

High rate of adefovir–lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients

P. Marcellin, F. Roudot-thoraval, T. Fontanges, 2010, European journal of gastroenterology & hepatology.

Ribavirin in combination therapy for HCV chronic infection in HIV patients: how to win the war after winning the first battle?

C. Trépo, M. Gagnieu, M. Maynard, 2007, Journal of hepatology.

Hepatitis B virus replication in primary macaque hepatocytes: Crossing the species barrier toward a new small primate model

F. Zoulim, I. Chemin, C. Trépo, 2010, Hepatology.

Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro

F. Zoulim, I. Chemin, C. Trépo, 2009, Antiviral therapy.

Nucleotide sequence of the woodchuck hepatitis virus surface antigen mRNAs and the variability of three overlapping viral genes.

M. Buendia, T. Möröy, C. Trépo, 1986, Gene.

Sequence-specific inhibition of duck hepatitis B virus reverse transcription by peptide nucleic acids (PNA).

F. Zoulim, P. Nielsen, M. Robaczewska, 2005, Journal of hepatology.

Serial transmission of spongiocytic hepatitis to woodchucks (possible association with a specific delta strain).

C. Trépo, L. Vitvitski, R. Paraná, 1995, Journal of hepatology.

Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins.

P. André, V. Lotteau, F. Zoulim, 2006, The Journal of general virology.

Hepatitis C virus genotypes in France: comparison of clinical features of patients infected with HCV type I and type II.

Q. S. Wang, C. Trépo, F. Bailly, 1994, Journal of hepatology.

Two French genotypes of hepatitis C virus: homology of the predominant genotype with the prototype American strain.

C. Trépo, S. Tong, L. Vitvitski, 1991, Gene.

Evidence of two major genotypes of hepatitis C virus in France and close relatedness of the predominant one with the prototype virus.

C. Trépo, S. Tong, L. Vitvitski, 1991, Journal of hepatology.

DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid

C. Trépo, M. Schleef, M. Major, 1995, Journal of virology.

Synthesis and antiviral activity of new carbonylphosphonate 2',3'-dideoxy-3'-thiacytidine conjugates.

J. Chermann, C. Trépo, M. Camplo, 1994, Antiviral research.

The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

P. Andersen, H. Thomas, G. Gerken, 1994, Journal of hepatology.

Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization.

U. Spengler, C. Trépo, G. Jung, 1997, DNA and cell biology.

A brief history of hepatitis milestones

C. Trépo, C. Trépo, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Hepatitis: After HCV cure, HBV cure?

C. Trépo, J. Lucifora, C. Trépo, 2015, Nature Reviews Gastroenterology &Hepatology.

Clinical impact of occult HBV infections.

I. Chemin, C. Trépo, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Orthotopic liver transplantation for idiopathic portal hypertension: indications and outcome.

M. Chevallier, J. Dumortier, J. Scoazec, 2001, Scandinavian journal of gastroenterology.

Intrafamilial prevalence of hepatitis B virus in Western Brazilian Amazon region: Epidemiologic and biomolecular study

F. Zoulim, C. Trépo, L. Vitvitski, 2006, Journal of gastroenterology and hepatology.

Phytohemagglutinin and concanavalin A activate hepatitis B virus in peripheral blood mononuclear cells of patients with chronic hepatitis B virus infection

F. Zoulim, P. Bouffard, C. Trépo, 1992, Journal of medical virology.

Inhibition of human and woodchuck hepatitis virus DNA polymerase by the triphosphates of acyclovir, 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and E-5-(2-bromovinyl)-2'-deoxyuridine.

E. De Clercq, C. Trépo, O. Hantz, 1984, Antiviral research.

Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens.

M. Chen, C. Trépo, P. Liljeström, 2000, Virology.

Immunoquantitation of von Willebrand factor (factor VIII-related antigen) in vinyl chloride exposed workers.

M. Marion, C. Trépo, O. Froment, 1992, Cancer letters.

Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses

F. Zoulim, C. Trépo, Perrine J Martin, 2002, Hepatology.

THE 2020 NOBEL PRIZE OF MEDICINE FOR THREE HEPATITIS C DISCOVERY PIONEERS : A MEDICAL HISTORY MILESTONE.

C. Trépo, 2021, Clinics and research in hepatology and gastroenterology.

Single‐step nested polymerase chain reaction for detection of different genotypes of hepatitis C virus

C. Trépo, S. Tong, L. Vitvitski, 1995, Journal of medical virology.

Hepatitis C virus among blood donors: follow‐up study

S. Sanjosé, M. Cortey, C. Trépo, 1994, Transfusion.

Assessment of Screening Tests for Transfusion-Associated Non-A Non-B Hepatitis

R. Battista, P. Durieux, C. Bréchot, 1993, International Journal of Technology Assessment in Health Care.

Transmission of serologically silent hepatitis B virus along with hepatitis C virus in two cases of posttransfusion hepatitis

J. Sninsky, J. Chévre, I. Chemin, 1992, Transfusion.

PCR detection of HCV RNA among French non-A, non-B hepatitis patients.

C. Trépo, S. Tong, L. Vitvitski, 1992, Archives of virology. Supplementum.

In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein.

C. Trépo, L. Cova, A. Kay, 1991, Virology.

DNA vaccination for the induction of immune responses against hepatitis C virus proteins.

C. Trépo, M. Major, L. Vitvitski, 1997, Vaccine.

Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma

I. Chemin, C. Trépo, S. Benjelloun, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Preliminary results of interferon-alpha therapy on woodchuck hepatitis virus-induced hepatocarcinogenesis: possible benefit in female transgenic mice.

M. Buendia, M. Chevallier, C. Trépo, 2001, Journal of hepatology.

Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from mauritius island

P. Roques, I. Chemin, C. Trépo, 2013, Hepatology.

A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus

F. Zoulim, C. Trépo, D. Durantel, 2004, Hepatology.

Frequency of hepatitis B virus e‐minus mutants varies among patients from different areas of China

Y. Wen, C. Trépo, H. Tu, 1997, Journal of medical virology.

EASL Meeting Report Report of the Monothematic EASL Conference on Liver Transplantation for Viral Hepatitis q

C. Trautwein, A. Burroughs, X. Forns, 2006 .

Studies on the role of HDV in an outbreak of fulminant hepatitis in Bangui (Central African Republic).

C. Trépo, A. Georges, L. Vitvitski, 1987, Progress in clinical and biological research.

Effect of interferon-alpha on experimental septal fibrosis of the liver - study with a new model.

C. Trépo, R. Paraná, M. M. Souza, 2001, Memorias do Instituto Oswaldo Cruz.

Effect of Interferon-α on Experimental Septal Fibrosis of the Liver Study with a New Model

C. Trépo, R. Paraná, Z. Andrade, 2022 .

Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature

M. Manns, H. Thomas, S. Sauleda, 2000 .

Epidemiology of hepatitis C virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group. (Hepatitis C European Network for Co-operative Research.

M. Manns, H. Thomas, S. Sauleda, 2000, European journal of gastroenterology & hepatology.

Suboptimal Response to Adefovir Dipivoxil Therapy for Chronic Hepatitis B in Nucleoside-Naive Patients is not due to Pre-Existing Drug-Resistant Mutants

L. Naesens, F. Zoulim, J. Neyts, 2008, Antiviral therapy.

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

C. Gibbs, J. Villeneuve, F. Zoulim, 2003, Journal of hepatology.

Comparative study of hepatitis C virus genotypes 1 and 3 in Salvador, Bahia Brazil.

M. Reis, R. Santos-Jesus, C. Trépo, 2003, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Acute sporadic non‐A, non‐B hepatitis in Northeastern Brazil: Etiology and natural history

C. Trépo, L. Vitvitski, R. Paraná, 1999, Hepatology.

Evolution of Hepatitis B and C serum markers: a still challenging issue

I. Chemin, C. Trépo, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection.

O. Guillaud, I. Chemin, C. Trépo, 2009, Journal of hepatology.

Effect of interferon-alpha 2b on cryoglobulinemia related to hepatitis C virus infection.

M. Richard, G. Kaplanski, C. Trépo, 1992, The Journal of infectious diseases.

Viral spliced RNA are produced, encapsidated and reverse transcribed during in vivo woodchuck hepatitis virus infection.

I. Chemin, C. Trépo, O. Hantz, 1992, Virology.

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

John B. Wong, Sanjeev Arora, Uwe Siebert, 2003 .

In Vitro Activity of 2,4-Diamino-6-[2-(Phosphonomethoxy)Ethoxy]-Pyrimidine against Multidrug-Resistant Hepatitis B Virus Mutants

F. Zoulim, S. Villet, J. Neyts, 2007, Antimicrobial Agents and Chemotherapy.

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure

P. Marcellin, F. Zoulim, M. Beaugrand, 2009, Liver international : official journal of the International Association for the Study of the Liver.

[Treatment of hepatitis B: new perspectives].

F. Zoulim, C. Trépo, C. Trépo, 2009, Gastroenterologie clinique et biologique.

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.

F. Zoulim, S. Villet, C. Trépo, 2008, Journal of hepatology.

Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal.

C. Trépo, S. Tong, L. Vitvitski, 1992, Virology.

Rapid screening for bacterial colonies harbouring tandem hepatitis B virus sequences by an oligonucleotide probe.

C. Trépo, S. Benjelloun, S. Tong, 1991, Journal of virological methods.

Prolonged duck hepatitis B virus replication in duck hepatocytes cocultivated with rat epithelial cells: A useful system for antiviral testing

C. Trépo, L. Cova, P. Gripon, 1989, Hepatology.

[Hepatitis B virus reactivation after allogeneic bone marrow transplantation in a patient previously cured of hepatitis B].

F. Zoulim, C. Trépo, M. Michallet, 1999, Gastroenterologie clinique et biologique.

The HBV HBX gene expressed in E. coli is recognised by sera from hepatitis patients.

F. Galibert, C. Trépo, E. Mandart, 1985, The EMBO journal.

Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?

C. Trépo, T. Bizollon, C. Trépo, 2002, Journal of hepatology.

Prediction of Sustained Virological Response by Ribavirin Plasma Concentration at Week 4 of Therapy in Hepatitis C virus Genotype 1 Patients

C. Trépo, P. Pradat, M. Gagnieu, 2008, Antiviral therapy.

Pegylated interferon alfa-2B (PEG-intron) mono-therapy is superior to interferon alfa-2B (intron A) for the treatment of chronic hepatitis C

E. Schiff, P. Marcellin, J. Hoefs, 2000 .

Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 16 cases

J. Dufour, C. Dumontet, C. Trépo, 2009, European journal of gastroenterology & hepatology.

Cutaneous vasculitis in a patient infected with hepatitis C virus. Detection of hepatitis C virus RNA in the skin by polymerase chain reaction

M. Richard, G. Kaplanski, C. Trépo, 1993, The British journal of dermatology.

Enhanced duck hepatitis B virus gene expression following aflatoxin B exposure

M. Chevallier, C. Wild, C. Borel, 1999, Hepatology.

Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter?

R. Aach, C. Trépo, P. Holland, 1983, Vox sanguinis.

Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients

M. Bertrand, J. Goudemand, C. Trépo, 2001, European journal of gastroenterology & hepatology.

Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis.

C. Trépo, C. Lai, P. Wu, 1981, The New England journal of medicine.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

P. Marcellin, J. Albrecht, S. Zeuzem, 1998, Lancet.

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.

M. Manns, T. Berg, G. Kukolj, 2011, Journal of hepatology.

The State of Hepatitis B and C in the Mediterranean and Balkan Countries: Report from a Summit Conference

M. Buti, H. Thomas, F. Roudot-thoraval, 2013, Journal of viral hepatitis.

Hepatitis B core antigen in hepatocytes of patients with chronic active hepatitis

C. Degott, C. Bréchot, C. Trépo, 1980, Digestive Diseases and Sciences.

Quantification and functional analysis of plasmacytoid dendritic cells in patients with chronic hepatitis C virus infection.

P. Couzigou, C. Bain, E. Decullier, 2004, The Journal of infectious diseases.

A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine

F. Zoulim, P. Landais, F. Degos, 2006, Journal of viral hepatitis.

Infection of a human hepatoma cell line by hepatitis B virus

Christian Trepo, C. Guguen-Guillouzo, D. Glaise, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Persistence of viral replication after anti-HBe seroconversion during antiviral therapy for chronic hepatitis B.

L. Stuyver, F. Zoulim, C. Trépo, 2000, Journal of hepatology.

Characterization of the Antiviral Effect of 2 9 ,3 9 -Dideoxy-2 9 , 3 9 -Didehydro- b - L -5-Fluorocytidine in the Duck Hepatitis B Virus Infection Model

M. Chevallier, F. Zoulim, C. Trépo, 1999 .

Selective detection of human hepatitis B virus surface and core antigens in peripheral blood mononuclear cell subsets by flow cytometry

F. Zoulim, J. Saurin, I. Chemin, 1994, Journal of viral hepatitis.

The role of duck hepatitis B virus and aflatoxin B1 in the induction of oxidative stress in the liver.

M. Chevallier, C. Wild, J. Cadet, 2001, Cancer detection and prevention.

Genotype determination in Moroccan hepatitis B chronic carriers.

P. Pineau, A. Dejean, I. Chemin, 2008, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.

F. Zoulim, O. Guillaud, I. Chemin, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

1094 100% SVR IN IL28B CC PATIENTS TREATED WITH 12 WEEKS OF TELAPREVIR, PEGINTERFERON AND RIBAVIRIN IN THE PROVE2 TRIAL

P. Marcellin, J. Pawlotsky, S. Pol, 2012 .

Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.

C. Sunyach, C. Trépo, L. Cova, 1999, Gastroenterology.

Antiviral effect of a-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles

R. Dwek, F. Zoulim, P. Roingeard, 2006 .

New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection

F. Zoulim, L. Mimms, I. Chemin, 1992, Journal of clinical microbiology.

n-Butyrate, a cell cycle blocker, inhibits early amplification of duck hepatitis B virus covalently closed circular DNA after in vitro infection of duck hepatocytes

C. Borel, C. Guguen-Guillouzo, C. Trépo, 1996, Journal of virology.

Integrated Viral Sequences may Contribute in cis and in trans to Hepatocarcinogenesis in Woodchuck Hepatitis Virus-infected Woodchucks

G. Fourel, M. Buendia, C. Trépo, 1994 .

Non‐A, non‐b hepatitis: identification of hepatitis‐b‐like virus particles in serum and liver

C. Trépo, L. Vitvitski, O. Hantz, 1980, Journal of medical virology.

Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.

F. Zoulim, C. Borel, C. Trépo, 2006, Journal of hepatology.

The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo.

F. Zoulim, C. Trépo, J. Imbach, 1999, Antiviral research.

Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles

F. Zoulim, J. Kraus, C. Borel, 1997, Antimicrobial agents and chemotherapy.

Early and frequent detection of HBxAg and/or anti‐HBx in hepatitis B virus infection

C. Trépo, E. Mandart, A. Kay, 1990, Hepatology.

Phosphorylation of DHBV pre-S: identification of the major site of phosphorylation and effects of mutations on the virus life cycle.

C. Borel, C. Sunyach, C. Trépo, 1998, Virology.

In vitro replication competence of a cloned hepatitis B virus variant with a nonsense mutation in the distal pre-C region.

C. Guguen-Guillouzo, C. Trépo, C. Diot, 1991, Virology.

Detection by immunofluorescence of a new "core-like" Ag/Ab system in liver and serum of patients with NANB hepatitis.

M. Schlaak, C. Trépo, L. Vitvitski, 2008, Liver.

Recurrence of hepatocellular carcinoma as a mixed hepatoblastoma after liver transplantation

M. Chevallier, J. Dumortier, J. Scoazec, 1999, Gut.

Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein.

C. Trépo, L. Cova, C. Rollier, 2000, Vaccine.

Maternally Transferred Antibodies from DNA-Immunized Avians Protect Offspring against Hepadnavirus Infection

C. Trépo, L. Cova, C. Rollier, 2000, Journal of virology.

HEP-05-0036.R1 Susceptibility to Antivirals of an HBV Strain With Mutations Conferring Resistance to Both Lamivudine and Adefovir

J. Villeneuve, F. Zoulim, C. Trépo, 2009 .

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B

L. Stuyver, F. Zoulim, D. Tavan, 2000, Hepatology.

Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

F. Zoulim, C. Trépo, O. Hantz, 2000, The Journal of infectious diseases.

Famciclovir in chronic hepatitis B: results of a dose-finding study.

C. Trépo, R. Boon, R. Boon, 2000, Journal of hepatology.

Inhibitory Effect of 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyl-Uracil on Duck Hepatitis B Virus Replication

M. Chevallier, F. Zoulim, C. Borel, 1998, Antimicrobial Agents and Chemotherapy.

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

R. Rubin, K. Kowdley, R. Ebrahimi, 2004, Gastroenterology.

A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B

P. Marcellin, B. Conway, G. Lau, 2004, Hepatology.

Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model

F. Zoulim, C. Trépo, C. Jamard, 2003, Antimicrobial Agents and Chemotherapy.

Inhibitory effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on woodchuck hepatitis virus replication in chronically infected woodchucks

C. Trépo, B. Chomel, K. Watanabe, 1990, Antimicrobial Agents and Chemotherapy.

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model.

C. Gibbs, M. Chevallier, F. Zoulim, 2003, Journal of hepatology.

Study of HBV replication capacity in relation to sequence variation in the precore and core promoter regions.

F. Zoulim, C. Trépo, S. Tong, 2004, Methods in molecular medicine.

In Vitro Characterization of the Anti-Hepatitis B Virus Activity and Cross-Resistance Profile of 2′,3′-Dideoxy-3′-Fluoroguanosine

David, F. Zoulim, C. Trépo, 2006, Antimicrobial Agents and Chemotherapy.

Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study

C. Trépo, F. Bonino, R. Saltzman, 2000 .

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

William M. Lee, M. Manns, J. Albrecht, 2002, Gastroenterology.

Hepatitis B Virus Impairs TLR9 Expression and Function in Plasmacytoid Dendritic Cells

P. Hainaut, F. Zoulim, M. Tommasino, 2011, PloS one.

Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti‐viral activity of clevudine for 12 weeks in patients with chronic hepatitis B

P. Marcellin, N. Leung, G. Lau, 2008, Alimentary pharmacology & therapeutics.

Inhibitory Effect of Penciclovir-Triphosphate on Duck Hepatitis B Virus Reverse Transcription

F. Zoulim, C. Trépo, E. Dannaoui, 1997 .

Inhibitory effect of penciclovir, the active metabolite of famciclovir, on the priming of hepadnavirus reverse transcription

F. Zoulim, C. Trépo, E. Dannaoui, 1995 .

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

F. Zoulim, C. Borel, Y. Cheng, 1996, Antimicrobial agents and chemotherapy.

Occult hepatitis B virus infection in HIV‐infected patients: Evaluation of biochemical, virological and molecular parameters

C. Trépo, B. Grinsztejn, M. Branco-Vieira, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

J. Villeneuve, F. Zoulim, S. Villet, 2006, Gastroenterology.

Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group.

P. Marcellin, D. Ouzan, A. Tran, 1996, Journal of hepatology.

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

C. Gibbs, P. Marcellin, F. Zoulim, 2004, Gastroenterology.

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

C. Trautwein, V. de Lédinghen, G. Gerken, 2012, Journal of hepatology.

Animal models for the understanding and control of HBV and HDV infections.

C. Trépo, L. Cova, L. Vitvitski, 1993, Journal of hepatology.

Effects of 2′‐fluorinated arabinosyl‐pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks

C. Trépo, O. Hantz, I. Fourel, 1992, Journal of medical virology.

Antiviral Activities of 2′-Fluorinated Arabinosyl—Pyrimidine Nucleosides

Christian Trepo, Raymond F. Schinazi, T. Chou, 1988 .

Therapeutic potential of acyclovir and of the interferons in HBV-related chronic active hepatitis due to HBV with or without HDV superinfection.

M. Chevallier, P. Chossegros, D. Ouzan, 1986, Journal of hepatology.

A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

E. Schiff, J. Hoefs, J. Albrecht, 2001, Hepatology.

A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

E. Schiff, J. Hoefs, J. Albrecht, 2001, Hepatology.

Adefovir dipivoxil (ADV) for the treatment of patients with chronic hepatitis B (CHB) failing lamivudine (LAM) therapy

P. Marcellin, F. Zoulim, S. Pol, 2003 .

DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.

M. Chevallier, F. Zoulim, C. Trépo, 2008, The Journal of general virology.

Antigenic cross-reactions between woodchuck hepatitis virus and human hepatitis B virus shown by immune electron microscopy.

C. Trépo, O. Hantz, L. Stannard, 1983, The Journal of general virology.

Virus-neutralizing monoclonal antibody to a conserved epitope on the duck hepatitis B virus pre-S protein

R. Sprengel, G. Deléage, H. Will, 1990, Journal of virology.

Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment

P. Marcellin, M. Chevallier, D. Valla, 1999, Hepatology.

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

P. Couzigou, M. Chevallier, P. Bedossa, 1995, The New England journal of medicine.

Interferon‐α2b therapy reduces liver fibrosis in chronic non‐A, non‐B hepatitis: A quantitative histological evaluation

X. Causse, M. Chevallier, P. Chossegros, 1993, Hepatology.

Occult B infection in the Brazilian northeastern region: a preliminary report.

I. Chemin, C. Trépo, R. Paraná, 2008, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.

J. Villeneuve, F. Zoulim, S. Villet, 2007, Journal of hepatology.

Genome Replication, Virion Secretion, and e Antigen Expression of Naturally Occurring Hepatitis B Virus Core Promoter Mutants

F. Zoulim, J. Wands, C. Trépo, 2003, Journal of Virology.

Hepatitis Viruses, Alcohol, and Tobacco in the Etiology of Hepatocellular Carcinoma in Italy

C. la Vecchia, S. Franceschi, F. Izzo, 2006, Cancer Epidemiology Biomarkers & Prevention.

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

J. Hoefs, J. Albrecht, G. Davis, 1998, The New England journal of medicine.

Diagnostic markers of viral hepatitis B and C.

F. Zoulim, C. Trépo, M. Petit, 1993, Gut.

Nucleoside analogs in the treatment of chronic viral hepatitis. Efficiency and complications.

F. Zoulim, C. Trépo, C. Trépo, 1994, Journal of hepatology.

Combination therapy with ARA-AMP and interferon of chronic active hepatitis B. Interim analysis of an ongoing study.

X. Causse, M. Chevallier, P. Chossegros, 1991, Journal of hepatology.

Removal of cell-bound lipoproteins: a crucial step for the efficient infection of liver cells with hepatitis C virus in vitro.

C. Trépo, D. Favre, P. Berthillon, 2001, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

Is lamivudine effective on precore/core promoter mutants of hepatitis B virus?

F. Zoulim, C. Trépo, 2000, Hepatology.

Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity.

L. Stuyver, M. Chevallier, F. Zoulim, 2000, Journal of hepatology.

Comparison of properties of woodchuck hepatitis virus and human hepatitis B virus endogenous DNA polymerases

C. Trépo, L. Vitvitski, O. Hantz, 1984, Antimicrobial Agents and Chemotherapy.

Therapeutic management of hepatitis B‐related cirrhosis

C. Trépo, P. Merle, C. Trépo, 2001, Journal of viral hepatitis.

Analysis of hepatitis B virus genotypes and pre‐core region variability during interferon treatment of HBe antigen negative chronic hepatitis B

F. Zoulim, C. Trépo, F. Habersetzer, 1996, Journal of medical virology.

Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape.

F. Zoulim, C. Trépo, L. Cotte, 2012, The Journal of infectious diseases.

Clearance of serum HBsAg and anti‐HBs seroconversion following antiviral therapy for chronic hepatitis B

P. André, F. Zoulim, C. Trépo, 2009, Journal of medical virology.

The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment

M. Manns, M. Buti, N. Voirin, 2004, Journal of medical virology.

A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection

P. Marcellin, B. Conway, G. Lau, 2003 .

PreS1 antigen/antibody patterns following interferon therapy in acute and chronic hepatitis B.

F. Zoulim, C. Dauguet, C. Trépo, 1994, Journal of hepatology.

Interferon Treatment of Viral Hepatitis

C. Trépo, F. Bailly, C. Trépo, 1997, BioDrugs.

Variability in the Precore and Core Promoter Regions of HBV Strains in Morocco: Characterization and Impact on Liver Disease Progression

F. Zoulim, I. Chemin, C. Trépo, 2012, PloS one.

74 THE ANTIVIRAL RESPONSE TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IS COMPARABLE IN LAMIVUDINE (LAM)-NAIVE AND LAM-EXPERIENCED SUBJECTS TREATED FOR CHRONIC HEPATITIS B (CHB)

M. Manns, T. Berg, M. Rizzetto, 2008 .

Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

P. Marcellin, D. Samuel, N. Ganne-Carrié, 2006, Journal of hepatology.

Rolling Circle Amplification, a Powerful Tool for Genetic and Functional Studies of Complete Hepatitis B Virus Genomes from Low-Level Infections and for Directly Probing Covalently Closed Circular DNA

F. Zoulim, I. Chemin, C. Trépo, 2008, Antimicrobial Agents and Chemotherapy.

DETECTION OF HEPATITIS B VIRUS DNA IN LIVER AND SERUM: A DIRECT APPRAISAL OF THE CHRONIC CARRIER STATE

C. Bréchot, F. Degos, C. Trépo, 1981, The Lancet.

Different patterns of decompensation in patients with alcoholic vs. non‐alcoholic liver cirrhosis

H. Tillmann, C. Trépo, P. Pradat, 2012, Alimentary pharmacology & therapeutics.

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, P. Marcellin, J. Albrecht, 2008 .

euHCVdb: the European hepatitis C virus database

Daniel Crisan, Christophe Combet, Christophe Geourjon, 2006, Nucleic Acids Res..

2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

C. Trautwein, G. Gerken, A. Tran, 2010 .

Hepatitis C and menopause interplay of age, gender, HCV replication and activity in progression and consequence for therapy

C. Trépo, P. Pradat, F. Bailly, 2009 .

162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial

E. Schiff, P. Marcellin, J. Albrecht, 2008 .

2007 4 WEEK THERAPY WITH THE NON-NUCLEOSIDIC POLYMERASE INHIBITOR BI207127 IN COMBINATION WITH PEGINTERFERON-ALFA2A AND RIBAVIRIN IN TREATMENT NAIVE AND TREATMENT EXPERIENCED CHRONIC HCV GT1 PATIENTS

C. Trautwein, G. Gerken, A. Lohse, 2010 .

Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).

P. Adeleine, C. Trépo, P. Pradat, 2006, Journal of hepatology.

HDV genotypes in the Western Brazilian Amazon region: A preliminary report.

C. Trépo, P. Tauil, R. Paraná, 2006, The American journal of tropical medicine and hygiene.

Demonstration of woodchuck hepatitis virus infection of peripheral blood mononuclear cells by flow cytometry and polymerase chain reaction.

I. Chemin, C. Trépo, D. Rigal, 1992, The Journal of general virology.

Schistosomiasis mansoni and viral B hepatitis in woodchucks.

C. Trépo, R. Paraná, J. Grimaud, 2001, Journal of Hepatology.

Monitoring of early events of experimental woodchuck hepatitis infection: studies of peripheral blood mononuclear cells by cytofluorometry and PCR.

I. Chemin, C. Trépo, D. Rigal, 1993, FEMS immunology and medical microbiology.

Presence and state of woodchuck hepatitis virus DNA in liver and serum of woodchucks: further analogies with human hepatitis B virus.

A. Dejean, C. Bréchot, C. Trépo, 1982, Virology.

Identification of Antigenic Regions of Duck Hepatitis B Virus Core Protein with Antibodies Elicited by DNA Immunization and Chronic Infection

G. Deléage, M. Robaczewska, C. Trépo, 2004, Journal of Virology.

Identification of major antigenic domains of duck hepatitis B virus pre-S protein by peptide scanning.

C. Trépo, L. Cova, C. Godinot, 1994, Virology.

Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study

P. Vanhems, C. Trépo, P. Paboriboune, 2019, PloS one.

Role of silent hepatitis B virus in chronic hepatitis B surface antigen(-) liver disease.

I. Chemin, C. Trépo, A. Kay, 2001, Antiviral research.

INFLUENCE OF DELTA INFECTION ON SEVERITY OF HEPATITIS B

D. Vergani, A. Gimson, Roger Williams, 1982, The Lancet.

Use of the cross-reactivity with hepatitis B virus antigens and antibodies for the demonstration of a woodchuck hepatitis virus 'e' antigen-antibody system.

C. Trépo, L. Vitvitski, O. Hantz, 1983, Journal of virological methods.

Transcription of woodchuck hepatitis virus in the chronically infected liver.

M. Buendia, T. Möröy, C. Trépo, 1985, The EMBO journal.

Clinical evaluation of the branched DNA assay for hepatitis B virus DNA detection in patients with chronic hepatitis B lacking hepatitis B e antigen and treated with interferon‐α

M. Chevallier, F. Zoulim, C. Trépo, 1998, Journal of viral hepatitis.

[Enzymatic amplification of sequences of viral nucleic acids. A methodological revolution promising new prospects in hepatology].

F. Zoulim, C. Trépo, J. Lamelin, 1992, Gastroenterologie clinique et biologique.

Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers.

M. Rizzetto, C. Trépo, S. Aricó, 1977, Gut.

Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon

G. Colucci, C. Trépo, F. Bailly, 1997, Journal of medical virology.

Occult HBV infection may represent a major risk factor of non‐response to antiviral therapy of chronic hepatitis C

M. Chevallier, F. Zoulim, O. Guillaud, 2007, Journal of medical virology.

Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers.

F. Zoulim, K. Rebbani, I. Chemin, 2011, The Journal of infection.

A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus.

F. Zoulim, C. Trépo, A. Lachaux, 2005, The Journal of general virology.

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

M. Manns, J. Albrecht, Z. Goodman, 2002, Gastroenterology.

Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure

B. Autran, F. Carrat, F. Zoulim, 2015, Gut.

Identification of novel recombinants of hepatitis B virus genotypes F and G in human immunodeficiency virus-positive patients from Argentina and Brazil.

C. Trépo, N. M. Araujo, F. Bessone, 2013, The Journal of general virology.

, Adrienne Mutants Occurring Hepatitis B Virus Core Promoter e Antigen Expression of Naturally Genome Replication , Virion Secretion

F. Zoulim, J. Wands, C. Trépo, 2003 .

Polyarteritis Nodosa Related to Hepatitis B Virus A Prospective Study with Long‐Term Observation of 41 Patients

C. Trépo, O. Lortholary, L. Guillevin, 1995, Medicine.

In vitro and in vivo replication capacity of the precore region defective hepatitis B virus variants.

C. Trépo, A. Prince, S. Tong, 1991, Journal of hepatology.

Rapid detection and further characterization of infection with hepatitis B virus variants containing a stop codon in the distal pre-C region.

F. Zoulim, C. Trépo, S. Tong, 1990, The Journal of general virology.

Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients

M. Manns, P. Tangkijvanich, H. Wedemeyer, 2018, The Journal of infectious diseases.

Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients

M. Chevallier, P. Chossegros, F. Zoulim, 1998, Journal of viral hepatitis.

Spectrum of liver disease and duck hepatitis B virus infection in a large series of chinese ducks with hepatocellular carcinoma

Shun-zhang Yu, C. Trépo, L. Cova, 1995, Hepatology.

Duck hepatitis B virus infection, aflatoxin B1 and liver cancer in domestic Chinese ducks.

C. Wild, R. Montesano, C. Trépo, 1994, British Journal of Cancer.

Duck Hepatocellular Carcinoma from a High Incidence Area: Analysis for Duck Hepatitis B Virus Infection and p53 Mutation

M. Hollstein, C. Wild, R. Montesano, 1994 .

Duck hepatitis B virus infection, aflatoxin B1 and liver cancer in ducks.

C. Trépo, L. Cova, M. Prave, 1993, Archives of virology. Supplementum.

Duck hepatitis B virus (DHBV) as a model for understanding hepadnavirus neutralization.

C. Trépo, L. Cova, A. Kay, 1993, Archives of virology. Supplementum.

Infection of a leukemic cell line (K562) by hepatitis B virus induces cell growth inhibition.

P. Bouffard, C. Trépo, J. Zeldis, 1993, Journal of hepatology.

Residues Critical for Duck Hepatitis B Virus Neutralization Are Involved in Host Cell Interaction

C. Borel, H. Will, C. Sunyach, 1999, Journal of Virology.

Progression to cirrhosis in hepatitis C patients: an age‐dependent process

N. Voirin, M. Chevallier, H. Tillmann, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Direct cloning and expression of PCR amplified DNA and RNA sequences: application to the hepadnaviruses nucleocapsid proteins.

I. Chemin, C. Trépo, O. Hantz, 1993, Journal of virological methods.

Different forms of hepatitis B virus DNA and expression of HBV antigens in peripheral blood mononuclear cells in chronic hepatitis B

F. Zoulim, P. Bouffard, C. Trépo, 1990, Journal of medical virology.

Duck hepatitis B virus can tolerate insertion, deletion, and partial frameshift mutation in the distal pre-S region

G. Deléage, R. Buckland, C. Trépo, 1989, Journal of virology.

Clinical relevance of total HCV Core antigen testing for hepatitis C monitoring and for predicting patients’ response to therapy

N. Voirin, P. Marcellin, C. Trépo, 2003, Journal of viral hepatitis.

Non‐F HBV/HDV‐3 coinfection is associated with severe liver disease in Western Brazilian Amazon

F. Zoulim, C. Trépo, R. Muwonge, 2019, Journal of medical virology.

Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction.

C. Trépo, L. Cova, J. Lamelin, 1994, Journal of hepatology.

Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study

P. Couzigou, P. Marcellin, J. Pawlotsky, 2005, Journal of viral hepatitis.

Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults

F. Zoulim, S. Ghosh, A. Manirakiza, 2018, PLoS neglected tropical diseases.

Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsid

C. Trépo, K. Mabrouk, J. Sabatier, 1993, Journal of medical virology.

Comparative study of hepatitis C virus genotypes 1 and 3 in Salvador, Bahia, Northeastern Brazil

M. Reis, R. Santos-Jesus, C. Trépo, 2002 .

HCV infection in northeastern Brazil: unexpected high prevalence of genotype 3a and absence of African genotypes.

C. Trépo, L. Vitvitski, R. Paraná, 2000, Arquivos de gastroenterologia.

[Prevalence of hepatitis C virus in urban and rural populations of northeast Brazil-pilot study].

C. Trépo, R. Paraná, H. Cotrim, 1995, Arquivos de gastroenterologia.

Discovery of a novel point mutation changing the HDAg expression of a hepatitis delta virus isolate from Central African Republic.

C. Trépo, L. Cova, J. Lamelin, 1993, The Journal of general virology.

Fulminant hepatitis with microvesicular steatosis (a histologic comparison of cases occurring in Brazil--Labrea hepatitis--and in central Africa--Bangui hepatitis).

C. Trépo, A. Prata, P. Ravisse, 1992, Revista da Sociedade Brasileira de Medicina Tropical.

Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).

I. Chemin, C. Trépo, A. Kay, 2013, Journal of virological methods.

Short Communication Identification of novel recombinants of hepatitis B virus genotypes F and G in human immunodeficiency virus-positive patients from Argentina and Brazil

C. Trépo, N. M. Araujo, F. Bessone, 2013 .

Decreased replication capacity of a duck hepatitis B virus mutant with altered distal pre-S region.

C. Trépo, I. Fourel, J. Li, 1991, Virus research.

HBV/HDV co‐infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers

F. Zoulim, C. Trépo, R. Muwonge, 2014, Journal of viral hepatitis.

Chronic Hepatitis C Polymerase Inhibitor, in Patients with an Investigational Hepatitis C Virus RNA Administration of Deleobuvir (BI 207127), Pharmacokinetics of Five-Day Oral Antiviral Effect, Safety, and

G. Kukolj, A. Lohse, M. Marquis, 2014 .

Antiviral Effect, Safety, and Pharmacokinetics of Five-Day Oral Administration of Deleobuvir (BI 207127), an Investigational Hepatitis C Virus RNA Polymerase Inhibitor, in Patients with Chronic Hepatitis C

G. Kukolj, A. Lohse, M. Marquis, 2013, Antimicrobial Agents and Chemotherapy.

Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors.

R. Dwek, F. Zoulim, P. Roingeard, 2007, The Journal of general virology.

Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?

C. Trépo, P. Pradat, 2009, Nature Reviews Gastroenterology &Hepatology.

Memory T-Cell-Mediated Immune Responses Specific to an Alternative Core Protein in Hepatitis C Virus Infection

F. Penin, C. Bain, J. Lavergne, 2004, Journal of Virology.

Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.

J. Sninsky, H. Wedemeyer, A. Potthoff, 2009, Journal of hepatology.

Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

H. El‐Serag, F. Negro, G. Davis, 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C.

P. Marcellin, C. Trépo, N. Boyer, 2000, Liver.

[Hepatitis C: which strategy in case of treatment failure ?].

A. Tran, C. Trépo, D. Larrey, 2008, Gastroenterologie clinique et biologique.

Long‐term administration of interferon‐α in non‐responder patients with chronic hepatitis C: follow‐up of liver fibrosis over 5 years

M. Chevallier, P. Chossegros, A. Desmoulière, 1999, Journal of viral hepatitis.

Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV‐coinfected patients

M. Chevallier, M. Chevallier, F. Zoulim, 2011, Journal of viral hepatitis.

In vivo selection of duck hepatitis B virus pre-S variants which escape from neutralization.

C. Sunyach, C. Trépo, L. Cova, 1997, Virology.

Detection of polyadenylated RNA in hepatitis B virus-infected peripheral blood mononuclear cells by polymerase chain reaction.

P. Bouffard, I. Chemin, C. Trépo, 1991, The Journal of infectious diseases.

A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France.

P. Vanhems, C. Trépo, B. Fantino, 2011, Journal of public health.

[Side effects of interferon-alpha].

C. Trépo, F. Bailly, T. Vial, 1996, Gastroenterologie clinique et biologique.

Treatment of HCV liver disease by recombinant interferon alpha.

C. Trépo, F. Bailly, N. Si, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Long-term high-dose interferon-α therapy delays Hepadnavirus-related hepatocarcinogenesis in X/myc transgenic mice

M. Chevallier, C. Trépo, S. Guerret, 2003, Oncogene.

Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand

P. Hainaut, S. Sangrajrang, M. Chevallier, 2011, Hepatitis research and treatment.

Efficient hepatitis C antigen immunohistological staining in sections of normal, cirrhotic and tumoral liver using a new monoclonal antibody directed against serum-derived HCV E2 glycoproteins.

P. Hainaut, I. Chemin, C. Trépo, 2007, Cancer letters.

Cryptic association of e antigen with different morphologic forms of hepatitis B surface antigen

C. Trépo, I. Mushahwar, L. Overby, 1979, Journal of medical virology.

PreS antigen expression and anti-preS response in hepatitis B virus infections: relationship to serum HBV-DNA, intrahepatic HBcAg, liver damage and specific T-cell response.

F. Zoulim, I. Chemin, C. Trépo, 1992, Archives of virology. Supplementum.

Hepatic intranuclear particles in patients with non-A, non-B hepatitis.

C. Trépo, L. Vitvitski, S. Peyrol, 1980, The New England journal of medicine.

Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma

P. Hainaut, J. Wands, J. Scoazec, 2008, British Journal of Cancer.

Molecular Mechanisms Underlying Hepatocellular Carcinoma

C. Trépo, P. Merle, C. Trépo, 2009, Viruses.

Origin and characterization of a human bipotent liver progenitor cell line.

Christian Trépo, Romain Parent, M. Marion, 2004, Gastroenterology.

Early stages of rabbit haemorrhagic disease virus infection monitored by polymerase chain reaction.

C. Trépo, L. Cova, N. Ruvoen-Clouet, 1996, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B.

Base Pairing in the Pregenome Encapsidation Signal of HBV: A Clue for the Prevalence of Naturally Occurring HBeAg-minus Precore Mutations

C. Trépo, S. Tong, L. Vitvitski, 1993 .

Replication of a molecularly cloned HBeAg negative hepatitis B virus variant in transfected HepG2 cells.

C. Trépo, C. Diot, P. Gripon, 1992, Archives of virology. Supplementum.

Rheumatological manifestations of hepatitis C: incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon.

F. Zoulim, C. Trépo, P. Miossec, 2005, Rheumatology.

A French prospective observational study of the treatment of chronic hepatitis C in drug abusers.

P. Couzigou, P. Chossegros, D. Ouzan, 2008, Gastroenterologie clinique et biologique.

The risk of hospital-acquired GB virus C infection: a pilot case-control study.

N. Voirin, C. Régis, P. Vanhems, 2003, The Journal of hospital infection.

Severe strongyloidiasis during interferon plus ribavirin therapy for chronic HCV infection.

C. Trépo, L. Vitvitski, R. Paraná, 2000, European Journal of Gastroenterology and Hepathology.

Influence of MHC class II genotype on outcome of infection with hepatitis C virus

Mark Thursz, Christian Trepo, H. Thomas, 1999, The Lancet.

Activation of Ki‐ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure

M. Marion, C. Trépo, O. Froment, 1991 .

Cells: Influence of Viral Load, Viral Genotype, and Cell Phenotype In Vivo Tropism of Hepatitis C Virus Genomic Sequences in Hematopoietic

C. Trépo, H. Lerat, M. Trabaud, 2010 .

In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype.

C. Trépo, H. Lerat, M. Trabaud, 1998, Blood.

Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study

P. Marcellin, O. Weiland, A. Alberti, 2002 .

Serological responses to different genotypes of hepatitis C virus in France

M. Cortey, S. de Sanjosé, C. Trépo, 1994, Journal of clinical microbiology.

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis

C. Trépo, P. Hervé, Y. Matillon, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[Is GB virus C alias "hepatitis" G virus involved in human pathology?].

C. Trépo, C. Fournier-Wirth, P. Hervé, 2003, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

Heterogeneity of hepatitis C virus genotypes in France.

M. Gouy, C. Trépo, S. Tong, 1994, The Journal of general virology.

Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection.

F. Zoulim, C. Bain, A. Fatmi, 2001, Gastroenterology.

Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA.

P. Simmonds, G. Gerken, P. Pontisso, 1996, Journal of hepatology.

Genetic immunization and comprehensive screening approaches in HLA‐A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen

C. Bain, C. Trépo, C. Barretto, 2004, Journal of medical virology.

Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

M. Manns, D. Franchimont, J. Sninsky, 2011, Hepatology.

124 IMPACT OF PNPLA3 (RS738409 C>G) POLYMORPHISM ON FIBROSIS PROGRESSION AND STEATOSIS IN CHRONIC HEPATITIS C

M. Manns, D. Franchimont, J. Devière, 2011 .

Innovative therapy for hepatocellular carcinoma: three-dimensional high-dose photon radiotherapy.

C. Trépo, F. Mornex, P. Merle, 2009, Cancer letters.

Analysis of a hepatitis delta virus isolate from the Central African Republic.

C. Trépo, S. Fillon, O. Hantz, 1998, Research in virology.

Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial.

N. Girard, C. Trépo, F. Mornex, 2006, International journal of radiation oncology, biology, physics.

Low prevalence of antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis.

C. Trépo, S. Bisot-Locard, H. Rousset, 1995, Journal of hepatology.

Establishment and characterization of a spontaneously immortalized myofibroblast cell line derived from a human liver angiosarcoma.

M. Marion, A. Desmoulière, C. Trépo, 2000, Journal of hepatology.

Predictors of the therapeutic response in hepatitis C. A 2013 update.

C. Trépo, M. Petit, Clémence Arnaud, 2014, Clinics and research in hepatology and gastroenterology.

Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications

H. Thomas, S. Sauleda, A. Alberti, 2007, Journal of viral hepatitis.

HCV and lymphoproliferative diseases.

C. Trépo, L. Vitvitski, P. Berthillon, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma.

M. Chevallier, F. Zoulim, Miran Kim, 2011, Journal of hepatology.

Inhibition of the expression of hepatitis A and B viruses (HAV and HBV) proteins by interferon in a human hepatocarcinoma cell line (PLC/PRF/5).

C. Trépo, A. Jouan, M. Petit, 1996, Journal of hepatology.

Non‐A, non‐b hepatitis virus: identification of a core antigen‐antibody system that cross reacts with hepatitis b core antigen and antibody

C. Trépo, L. Vitvitski, O. Hantz, 1981, Journal of medical virology.

ras gene mutations in vinyl chloride‐induced liver tumours are carcinogen‐specific but vary with cell type and species

H. Bartsch, M. Marion, J. Swenberg, 2000, International journal of cancer.

Absence of p53 mutation at codon 249 in duck hepatocellular carcinomas from the high incidence area of Qidong (China).

M. Hollstein, R. Montesano, C. Trépo, 1994, Carcinogenesis.

Transjugular intra-hepatic portosystemic shunt for refractory variceal bleeding

J. Dumortier, C. Trépo, P. Valette, 2001, European journal of gastroenterology & hepatology.

Long-term results of liver transplantation for Wilson's disease.

C. Trépo, R. Gincul, P. Paliard, 2008, Gastroenterologie clinique et biologique.

[Fulminant hepatitis B virus associated with acute pancreatitis. Report of two cases (author's transl)].

J. Motin, C. Trépo, J. Grimaud, 1981, Annales de medecine interne.

Fibrinolytic therapy for portal vein thrombosis

C. Trépo, F. Bissuel, T. Bizollon, 1991, The Lancet.

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial.

N Tygstrup, J. Neuberger, B. Portmann, 1993, Gastroenterology.

Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study

H. Thomas, A. Fabre, R. Goldin, 2003, Gut.

Detection of rabbit haemorrhagic disease virus isolates and sequence comparison of the N-terminus of the capsid protein gene by the polymerase chain reaction.

C. Trépo, L. Cova, G. Le Gall, 1995, Research in veterinary science.

Prevalence of hepatitis E virus IgG antibodies in patients from a referral unit of liver diseases in Salvador, Bahia, Brazil.

C. Trépo, R. Paraná, H. Cotrim, 1997, The American journal of tropical medicine and hygiene.

Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study.

D. Ouzan, T. Fontanges, S. Pol, 2007, Gastroenterologie clinique et biologique.

[Glucagonoma revealed by necrolytic migratory erythema].

J. Scoazec, C. Trépo, M. Chevallier, 2003, Gastroentérologie Clinique et Biologique.

A non-A non-B hepatitis epidemic in a HB antigen-free haemodialysis unit. Demonstration of serological markers of non-A non-B virus.

C. Trépo, L. Vitvitski, A. Couroucé, 1980, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

Hepatitis C screening practices among private practitioners: impact of an information campaign.

C. Trépo, F. Bailly, E. Caillat-Vallet, 2004, Gastroenterologie clinique et biologique.

Should Donors with a History of Jaundice Still be Rejected

M. Goldfield, L. Seeff, R. Aach, 1981 .

Serial transmission of a human non A-non B hepatitis viral strain to HBV-protected chimpanzees: successive histological and ultrastructural studies.

C. Degott, F. Degos, C. Trépo, 2008, Liver.

“Total HCV core antigen assay”: a new marker of viremia and it's application in diagnosis

P. Marcellin, A. Zanetti, C. Trépo, 2002 .

[Medical follow-up of patients with positive serology for hepatitis C virus].

C. Trépo, P. Pradat, F. Bailly, 2001, Gastroenterologie clinique et biologique.

Predictive value of alt levels on histological findings in chronic hepatitis C: a European collaborative study

P. Marcellin, O. Weiland, A. Alberti, 2001 .

Enveloped particles in the serum of chronic hepatitis C patients.

C. Trépo, M. Petit, S. Peyrol, 2005, Virology.

Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients

P. Pineau, C. Trépo, P. Paboriboune, 2018, Virologica Sinica.

Expression of Noncovalent Hepatitis C Virus Envelope E1-E2 Complexes Is Not Required for the Induction of Antibodies with Neutralizing Properties following DNA Immunization

C. Trépo, O. Vidalin, G. Maertens, 1999, Journal of Virology.

Mapping of a Conformational Epitope Shared between E1 and E2 on the Serum-derived Human Hepatitis C Virus Envelope*

C. Trépo, M. Petit, Y. Michal, 2003, Journal of Biological Chemistry.

Management of nonresponsive hepatitis C

C. Trépo, P. Pradat, F. Bailly, 2010, Expert review of anti-infective therapy.

Immune responses against hepatitis C virus structural proteins following genetic immunisation.

C. Trépo, M. Major, I. Nakano, 1998, Developments in biological standardization.

Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir

P. Tangkijvanich, H. Wedemeyer, C. Trépo, 2017 .

Analysis of B‐lymphocyte differentiation in patients infected with hepatitis C virus

C. Trépo, T. Defrance, P. Merle, 2004, Journal of medical virology.

Magnitude and management of HCV infection in France

C. Trépo, F. Bailly, 1996, Digestive Diseases and Sciences.

[Hepatitis C virus infection and thyroid diseases].

F. Zoulim, C. Trépo, C. Broussolle, 1999, La Revue de medecine interne.

Pretreatment Predictive Factors for Hepatitis C Therapy Outcome: Relevance of Anti-E1E2 Antibodies Compared to Ip-10 and Il28B Genotypes

I. Chemin, C. Trépo, P. Pradat, 2013, Antiviral therapy.

A novel vector for the study of hepatitis delta virus replication.

C. Trépo, O. Hantz, A. Kay, 1998, Journal of virological methods.

A new viral agent, SEN virus (SENV), has been detected in patients from several countries: the pathogenic role of SENV in coinfections with hepatitis B virus or hepatitis C virus should be investigated.

I. Chemin, C. Trépo, R. Paraná, 2002, The Journal of infectious diseases.

Generation of a 1.5‐kb cDNA fragment of the hepatitis C virus genome by overlap extension

C. Trépo, S. Tong, L. Vitvitski, 1991, Journal of medical virology.

Anticorps anti-HCV et hépatites post-transfusionnelles non-A non-B

C. Trépo, J. Ducos, A. Marinière, 1990 .

Characterization of the double-stranded RNA responses in human liver progenitor cells.

C. Trépo, D. Durantel, M. Petit, 2008, Biochemical and biophysical research communications.

Screening campaign of hepatitis C among underprivileged people consulting in health centres of Lyon area, France.

P. Vanhems, C. Trépo, F. Bailly, 2007, European journal of public health.

Two low molecular weight peptides as common determinants to different molecular forms and specificities of hepatitis b e antigen (hbeag)

C. Trépo, L. Vitvitski, O. Hantz, 1980, Journal of medical virology.

New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.

C. Trépo, C. Ducerf, T. Bizollon, 1995, Journal of hepatology.

New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin. Question and answer

Sherlock, C. Trépo, C. Ducerf, 1995 .

[Decarboxyprothrombin: importance in the diagnosis of hepatocellular carcinoma].

C. Trépo, M. Gelineau, C. Bon, 1998, Annales de Biologie Clinique.

Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC).

C. Trépo, J. Taieb, L. Bonyhay, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequence analysis of PCR amplified hepatitis C virus cDNA from French non-A, non-B hepatitis patients.

C. Trépo, S. Tong, L. Vitvitski, 1992, Archives of virology. Supplementum.

Antiblastic drug targeting to hepatocellular carcinoma cells: a potential therapeutic improvement?

C. Trépo, P. Merle, 1998, Italian journal of gastroenterology and hepatology.

Influence of aminotransferase values on liver stiffness measurement: the case of HIV‐infected patients with acute viral hepatitis B or C

C. Trépo, P. Pradat, P. Miailhes, 2009, HIV medicine.

Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma.

Miran Kim, J. Wands, S. M. de la Monte, 2005, Journal of hepatology.

Treatment ofpolyarteritis nodosa related to hepatitis Bvirus withinterferon-alpha andplasma exchanges

C. Trépo, J. Pourrat, F. Rossi, 1994 .

Detection of small and large genomes of hepatitis D virus in serum of patients with hepatitis D

C. Trépo, J. Lamelin, L. Vitvitski, 1994, Journal of medical virology.

The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C

H. Wedemeyer, A. Potthoff, C. Trépo, 2010, Hepatology.

Expression of E1E2 on Hepatitis C RNA-Containing Particles Released from Primary Cultured Human Hepatocytes Derived from Infected Cirrhotic Livers

M. Bilodeau, C. Trépo, M. Petit, 2010, Intervirology.

Long‐term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes

C. Trépo, M. Petit, Elisabeth Errazuriz, 2011, Hepatology.

Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C.

J. Scoazec, C. Trépo, P. Merle, 2004, Journal of hepatology.

Iconography : Hépatite aiguë cytolytique induite par l'imatinib mesylate

F. Zoulim, J. Scoazec, C. Trépo, 2004 .

Protein in Hepatitis C Virus Infection Responses Specific to an Alternative Core Memory T-Cell-Mediated Immune

F. Penin, J. Lavergne, C. Trépo, 2014 .

[619] PREDICTION OF SUSTAINED VIROLOGICAL RESPONSE BY RIBAVIRIN PLASMA CONCENTRATION AT WEEK 4 DURING PEGYLATED-INTERFERON/RIBAVIRIN COMBINATION THERAPY IN HCV PATIENTS

C. Trépo, P. Pradat, M. Gagnieu, 2007 .

[Autoimmunization induced by interferon alpha therapy in chronic hepatitis C].

M. Chevallier, F. Zoulim, C. Trépo, 2004, Gastroenterologie clinique et biologique.

In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides

C. Trépo, O. Vidalin, M. Major, 1996, Antimicrobial agents and chemotherapy.

A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in patients chronically infected with HBV

P. Marcellin, B. Conway, G. Lau, 2003 .

Therapy of chronic delta hepatitis with alpha- and beta-interferon.

C. Trépo, J. Gaudin, 1993, Progress in clinical and biological research.

Treatment of chronic hepatitis C: another therapeutic option.

C. Trépo, F. Bailly, T. Bizollon, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus

F. Zoulim, C. Trépo, D. Durantel, 2004, Hepatology.

Human hepatocellular carcinoma transplanted in nude mice: a relevant experimental model to assess tumoral destruction by alcoholization.

C. Trépo, I. Fourel, C. Gouillat, 1994, The Journal of surgical research.

Hepatitis B virus infection

H. Chan, C. Trépo, Anna S.F. Lok, 2014, The Lancet.

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis. The EATHIS Eco Research Group. European Acute Transfusion Hepatitis Interferon Study.

C. Trépo, Y. Matillon, C. Colin, 1997, European Journal of Clinical Microbiology and Infectious Diseases.

Mononeuritis in acute viral hepatitis.

C. Trépo, J. Benhamou, G. Pelletier, 1985, Digestion.

Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.

F. Zoulim, I. Chemin, C. Trépo, 2018, Clinics and research in hepatology and gastroenterology.